BioNTech (NASDAQ:BNTX) Stock Price Down 1.3% - What's Next?

Shares of BioNTech SE (NASDAQ:BNTX - Get Free Report) dropped 1.3% on Wednesday . The stock traded as low as $115.51 and last traded at $115.91. Approximately 88,213 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 805,779 shares. The stock had previously closed at $117.39.

Analysts Set New Price Targets

A number of research analysts have commented on BNTX shares. TD Cowen decreased their price objective on BioNTech from $132.00 to $122.00 and set a "hold" rating on the stock in a research report on Tuesday, November 5th. BMO Capital Markets reissued an "outperform" rating on shares of BioNTech in a report on Monday, December 2nd. Evercore ISI upgraded shares of BioNTech from an "in-line" rating to an "outperform" rating and upped their target price for the company from $110.00 to $125.00 in a research report on Tuesday, November 19th. JPMorgan Chase & Co. lowered their price target on shares of BioNTech from $124.00 to $122.00 and set a "neutral" rating for the company in a research report on Tuesday, November 26th. Finally, Canaccord Genuity Group boosted their price target on shares of BioNTech from $171.00 to $171.44 and gave the stock a "buy" rating in a research note on Wednesday, November 27th. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $140.76.

BioNTech Stock Down 4.9 %

The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a 50 day simple moving average of $113.54 and a 200-day simple moving average of $100.73. The stock has a market cap of $26.53 billion, a P/E ratio of -53.15 and a beta of 0.22.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of ($1.26) by $2.07. The firm had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business's revenue was up 38.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.73 EPS. On average, equities research analysts forecast that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Large investors have recently bought and sold shares of the company. Slow Capital Inc. increased its holdings in BioNTech by 12.0% in the 2nd quarter. Slow Capital Inc. now owns 51,080 shares of the company's stock worth $4,105,000 after purchasing an additional 5,467 shares in the last quarter. Van ECK Associates Corp raised its holdings in BioNTech by 1.9% in the 2nd quarter. Van ECK Associates Corp now owns 119,901 shares of the company's stock valued at $9,635,000 after buying an additional 2,192 shares during the last quarter. Investmentaktiengesellschaft Fuer Langfristige Investoren TGV grew its holdings in BioNTech by 41.4% during the 2nd quarter. Investmentaktiengesellschaft Fuer Langfristige Investoren TGV now owns 20,500 shares of the company's stock worth $1,647,000 after acquiring an additional 6,000 shares during the last quarter. TD Asset Management Inc increased its position in BioNTech by 6.1% in the 2nd quarter. TD Asset Management Inc now owns 7,590 shares of the company's stock valued at $612,000 after acquiring an additional 435 shares during the period. Finally, Candriam S.C.A. raised its stake in shares of BioNTech by 261.2% during the second quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock valued at $46,526,000 after acquiring an additional 418,695 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.